INSIGHTS AND PERSPECTIVES

LONDON — GlaxoSmithKline announced the results from the first of eight phase-3 clinical trials that examined the efficacy of albiglutide in the treatment of Type 2 diabetes.

The Harmony 7 trial was a 32-week, head-to-head, open-label, noninferiority study that compared albiglutide, an investigational once weekly glucagon-like peptide-1 agonist, with once-daily liraglutide. According to the results, patients administered GSK's drug saw a 0.78% reduction in HbA1C, while patients administered liraglutide saw a 0.99% reduction in HbA1C.

WASHINGTON — Up to 152 million people plan to shop Black Friday weekend, compared with the 138 million who planned to do so last year, according to a preliminary Black Friday shopping survey, conducted for the National Retail Federation by BIGresearch. According to the survey, 74 million people said they will definitely hit the stores and another 77 million are waiting to see if the bargains are worth the hassle of Black Friday.

NEW YORK — Consumer loyalty isn't driven by rewards programs but shopping experiences that create strong psychological connections, according to a new report from PwC.

WASHINGTON — Despite continued economic uncertainty, more Americans are expected to choose family over finances, resulting in first significant increase in any holiday travel this year, AAA announced Thursday.

AAA forecasts 42.5 million Americans will travel 50 miles or more from home during the Thanksgiving holiday weekend, a 4% increase from people who traveled one year ago. This is the first significant increase in any holiday travel this year.

MOUNTAIN VIEW, Calif. — The increase in the number of people with rheumatoid arthritis, and the challenges posed to drug makers by generics, is encouraging the development of new drugs for the disease, according to a new report by Frost & Sullivan.

PRINCETON, N.J. — Bristol-Myers Squibb and AstraZeneca presented an analysis Wednesday of 14 clinical trials at the American Heart Association's Scientific Sessions in Orlando, Fla., the companies said.

The phase-2b and phase-3 trials all involved the investigational Type 2 diabetes drug dapagliflozin and, the companies said, showed that use of the drug did not lead to an unacceptable risk to adult patients' cardiovascular health compared with other treatments.

PARSIPPANY, N.J. — Consumers are gravitating toward "natural" over-the-counter remedies, according to a new Kline report, "Natural OTCs 2011: Impact of Non-Drug Products on the U.S. OTC Market," released Wednesday.

While the U.S. traditional nonprescription drugs industry registered an average compound annual growth rate of 2.5% between 2005 and 2010, the market for natural OTC remedies has grown at a CAGR of 5.9% per year from 2009 to 2011, according to the research study.

NEW YORK — Shoppers today are more knowledgeable than ever when it comes to finding deals on their favorite products, and many won't even set foot in a store until they have an idea of their potential savings, according to the Deloitte/Harrison Group annual American Pantry Survey.